Maria Laura Vieri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Laura Vieri has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Mariana Petronela Hanga
Department of Biochemical Engineering, The Advanced Centre for Biochemical Engineering University College London London UK
2 shared publications - Michael Sulu
Department of Biochemical Engineering, The Advanced Centre for Biochemical Engineering University College London London UK
2 shared publications - William Gordon
Department of Biochemical Engineering, The Advanced Centre for Biochemical Engineering University College London London UK
2 shared publications Ajay Nirula
Lilly Biotechnology Center, San Diego, CA, USA
1 shared publication- Andrew D. Rowan
Skeletal Research Group, Institute of Genetic Medicine, Newcastle University, Newcastle-upon-Tyne, United Kingdom
1 shared publication Annie Peacock
School of Infection and Immunity, University of Glasgow, Glasgow, UK
1 shared publication
Latest Publications
- Open Access
- 6 September 2026
- Published by Wiley in Food Bioengineering
- Vol. 5 (3) , 389-404
Under‐Explored Species, Breeds and Cell Types With Potential for Cultivated Meat Production
To achieve scale and cost parity, cultivated meat production must overcome critical bottlenecks such as the quality of starting cells. This review presents a systematic evaluation of unconventional and non‐traditional sources of cells as targeted strategies to address these specific manufacturing challenges. By moving beyond traditional domesticated livestock as sources for starting cells, this review highlights how under‐explored species or breeds offer distinct biological advantages with potential to directly improve bioprocess efficiency by leveraging natural traits such as enhanced proliferation rates, potential for spontaneous immortalisation and optimised differentiation. Furthermore, diversifying cell sourcing not only accelerates the path to commercial‐scale production but also enables the creation of novel cultivated meat products and other high‐value animal‐derived materials.
- 6 September 2026
- Published by Wiley in Food Bioengineering
- Vol. 5 (3) , 389-404
Open AccessUnder‐Explored Species, Breeds and Cell Types With Potential for Cultivated Meat Production
To achieve scale and cost parity, cultivated meat production must overcome critical bottlenecks such as the quality of starting cells. This review presents a systematic evaluation of unconventional and non‐traditional sources of cells as targeted strategies to address these specific manufacturing challenges. By moving beyond traditional domesticated livestock as sources for starting cells, this review highlights how under‐explored species or breeds offer distinct biological advantages with potential to directly improve bioprocess efficiency by leveraging natural traits such as enhanced proliferation rates, potential for spontaneous immortalisation and optimised differentiation. Furthermore, diversifying cell sourcing not only accelerates the path to commercial‐scale production but also enables the creation of novel cultivated meat products and other high‐value animal‐derived materials.
- Open Access
Serum-free media development and validation for cultivation of C2C12 immortalised murine myosatellite cell line for cultivated meat
The development of cost-effective, serum-free media is critical for scalable cultivated meat production. This study used high-throughput screening through a Design of Experiments (DoE) approach to develop an animal-free, serum-free medium (MMM1) specifically for the C2C12 murine myoblasts model cell line with applicability in cultivated meat research including for pet food. Low cost, food-grade inputs such as methylcellulose and spirulina extract resulted in significant cell growth improvements. The optimised MMM1 formulation containing low cost, food-grade inputs, achieved cumulative population doublings comparable to 10% (v/v) fetal bovine serum over four consecutive passages. Furthermore, MMM1 supported scalable cell expansion on commercially available dextran-based microcarriers (Cytodex-3) in both static and agitated conditions in spinner flasks, matching growth rates of serum-based controls. Finally, transitioning to a food-grade DMEM/F12 basal medium maintained cell proliferation equivalent to the pharmaceutical-grade DMEM/F12, but at a significantly lower cost, thus offering a viable strategy to substantially reduce biomanufacturing costs which is a critical challenge in cultivated meat production. Highlights: A serum-free medium formulation for C2C12 murine myoblasts (MMM1) C2C12 growth in MMM1 comparable to serum-based medium C2C12 growth in MMM1 in microcarrier culture as effective as serum-based medium MMM1 can be translated to be animal-free and fully food-grade Graphical
Open AccessSerum-free media development and validation for cultivation of C2C12 immortalised murine myosatellite cell line for cultivated meat
The development of cost-effective, serum-free media is critical for scalable cultivated meat production. This study used high-throughput screening through a Design of Experiments (DoE) approach to develop an animal-free, serum-free medium (MMM1) specifically for the C2C12 murine myoblasts model cell line with applicability in cultivated meat research including for pet food. Low cost, food-grade inputs such as methylcellulose and spirulina extract resulted in significant cell growth improvements. The optimised MMM1 formulation containing low cost, food-grade inputs, achieved cumulative population doublings comparable to 10% (v/v) fetal bovine serum over four consecutive passages. Furthermore, MMM1 supported scalable cell expansion on commercially available dextran-based microcarriers (Cytodex-3) in both static and agitated conditions in spinner flasks, matching growth rates of serum-based controls. Finally, transitioning to a food-grade DMEM/F12 basal medium maintained cell proliferation equivalent to the pharmaceutical-grade DMEM/F12, but at a significantly lower cost, thus offering a viable strategy to substantially reduce biomanufacturing costs which is a critical challenge in cultivated meat production. Highlights: A serum-free medium formulation for C2C12 murine myoblasts (MMM1) C2C12 growth in MMM1 comparable to serum-based medium C2C12 growth in MMM1 in microcarrier culture as effective as serum-based medium MMM1 can be translated to be animal-free and fully food-grade Graphical
- Open Access
- 8 March 2026
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (6) , 819-831
PAR2 deletion in the osteoblast lineage affords long-term cartilage protection in experimental osteoarthritis
- 8 March 2026
- Published by Elsevier in Osteoarthritis and Cartilage
- Vol. 34 (6) , 819-831
Open AccessPAR2 deletion in the osteoblast lineage affords long-term cartilage protection in experimental osteoarthritis
- Open Access
- 18 October 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (3) , 534-546
Spatial profiling of giant cell arteritis tissues reveals immune heterogeneity and potential predictors of glucocorticoid response
- 18 October 2025
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (3) , 534-546
Open AccessSpatial profiling of giant cell arteritis tissues reveals immune heterogeneity and potential predictors of glucocorticoid response